JCP
CLVS

Jabre Capital Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Jabre Capital Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-30,000
Closed -$881K – 108
2018
Q3 		$881K Sell
30,000
-10,000
-25% -$387K 0.29% 66
2018
Q2 		$1.82M Buy
+40,000
New +$1.95M 0.12% 65

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Jabre Capital Partners's CLVS Position: Q4 2018 in Review

Jabre Capital Partners sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 30,000 shares — an estimated $881K sold.

Jabre Capital Partners first reported a position in CLVS in Q2 2018 and held it in 2 quarters. The position peaked at $1.82M in Q2 2018. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Jabre Capital Partners reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Jabre Capital Partners sold 30,000 Clovis Oncology, Inc. shares in Q4 2018, an estimated $881K.
  • Jabre Capital Partners first reported a position in Clovis Oncology, Inc. in Q2 2018 and held it in 2 quarters.
  • Jabre Capital Partners's Clovis Oncology, Inc. position peaked at $1.82M in Q2 2018.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Jabre Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.